Details

Autor(en) / Beteiligte

• Weiler, John M., MD
• Brannan, John D., PhD
• Randolph, Christopher C., MD
• Hallstrand, Teal S., MD
• Parsons, Jonathan, MD
• Silvers, William, MD
• Storms, William, MD
• Zeiger, Joanna, MS, PhD
• Bernstein, David I., MD
• Blessing-Moore, Joann, MD
• Greenhawt, Matthew, MD, MBA, MSc
• Khan, David, MD
• Lang, David, MD
• Nicklas, Richard A., MD
• Oppenheimer, John, MD
• Portnoy, Jay M., MD
• Schuller, Diane E., MD
• Tilles, Stephen A., MD
• Wallace, Dana, MD

Titel

Exercise-induced bronchoconstriction update—2016

Ist Teil von

• Journal of allergy and clinical immunology, 2016-11, Vol.138 (5), p.1292-1295.e36

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Electronic Journals Library - Freely accessible e-journals

Beschreibungen/Notizen

• The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence- and consensus-based document.